Drug intelligence / Profile preview

Wei Chang Hao

Development stage: Unknown
Lead developer: The First Hospital of Nanchang
Administration: Oral

Overview

Wei Chang Hao is a drug being investigated for its use in combination with quadruple therapy for the eradication of Helicobacter pylori infection. It is administered orally at a dosage of 2,000 mg, three times daily. In clinical trials, it is taken for 14 days concurrently with antibiotics and then continued for an additional 4 weeks after the antibiotic regimen is completed.

Other names: 渭昶好

Beyond the preview

Go deeper on Wei Chang Hao.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wei Chang Hao.

Explore the full profile